CHUGAI PHARMACEUTICAL CO., LTD.

Home > News > 2010

2010

 RSS

December

Dec 21
  • R&D
Joint Development of Therapeutic Cancer Vaccine WT4869
[PDFPDF 68KB]

November

Nov 29
  • Corporate
Organizational Restructuring and Personnel Changes
[PDFPDF 171KB]

October

Oct 26
  • Product
Chronic Hepatitis C Treatment, Pegasys®, and Antiviral Drug, Copegus®,
Filed for Additional Indication of Compensated Liver Cirrhosis Related to Hepatitis C
[PDFPDF 133KB]
Oct 25
  • Corporate
Personnel Changes
[PDFPDF 163KB]
Oct 22
  • Corporate
Revision of Financial Outlook for Fiscal Year 2010
(January 1 - December 31, 2010)
[PDFPDF 39KB]
Oct 20
  • CSR
Relief Efforts Support for the Serious Flood Disaster Area in Pakistan
[PDFPDF 118KB]
Oct 19
  • R&D
Data Presented at the American Society for Bone and Mineral Research
on Japanese Phase III Study of 'Eldecalcitol,' an Active Vitamin D3 Derivative
[PDFPDF 165KB]
Oct 18
  • Product
ACTEMRA/RoACTEMRA (tocilizumab) supplemental marketing authorizations submitted in the US and Europe for the treatment of systemic Juvenile Idiopathic Arthritis
- New hope for children suffering from debilitating arthritis -
[PDFPDF 256KB]
Oct 18
  • R&D
Chugai’s Novel Antibody Engineering Technology Published in Nature Biotechnology
- Enabling single antibody molecule to block the function of target antigen multiple times -
[PDFPDF 328KB]
Oct 15
  • Corporate
Introduction of a Personnel Program to Provide Contract Workers with Opportunities to Change to Full Employment
- To further promote motivated human resources -
[PDFPDF 167KB]
Oct 14
  • Corporate
F. Hoffmann-La Roche Announces Third Quarter Sales 2010
[PDFPDF 17KB]
Oct 14
  • Product
Supply Plan of "Tamiflu®" Anti-influenza Drug
[PDFPDF 166KB]
Oct 07
  • CSR
Contribution of Para-transit Vehicles to Welfare Services
[PDFPDF 214KB]
Oct 04
  • CSR
Chugai Presents an Anti-Cancer Charity “Medicine and Humor”
[PDFPDF 195KB]

September

Sep 28
  • Corporate
Information about Plan to Appoint a New Accounting Auditor
[PDFPDF 78KB]
Sep 09
  • CSR
Trial Use of Electric Vehicles - Enhancement of Preventive Measures Against Global Warming -
[PDFPDF 185KB]
Sep 08
  • Product
Anti-Angiogenic Anti-Cancer Agent Avastin® Condition for Approval (All Patients Surveillance) Removed in Japan
[PDFPDF 173KB]
Sep 02
  • Product
Anti-Cancer Agent, Xeloda® Filed for Advanced or Refractory Gastric Cancer By “New Drug Application Based on Evidence in the Public Domain”
[PDFPDF 163KB]
Sep 01
  • CSR
Renewal of “Cancer Information Guide,” a Website for Patients: - Maximizing Convenience through Unique Built-in Search Engine -
[PDFPDF 153KB]

August

Aug 30
  • CSR
Awareness Enhancement of Colon Diseases with Display of Giant-Sized Balloon Art, "Japanese Version of a Giant Colon"
- "Relay for Life Japan 2010" -
[PDFPDF 255KB]
Aug 06
  • Corporate
Organizational Restructuring and Personnel Changes
[PDFPDF 135KB]
Aug 04
  • Product
"ACTEMRA®" Humanized Anti-Human IL-6 Receptor Monoclonal Antibody Conditions for Approval (All Patients Surveillance) Lifted in Japan
[PDFPDF 192KB]

July

Jul 30
  • Corporate
Assisting Work-Life Balance
[PDFPDF 196KB]
Jul 28
  • CSR
New Interactive Videos at Permanent Exhibit "Dr. Kitanomaru's Bio Pharmaceutical Laboratory" at the Science Museum
[PDFPDF 230KB]
Jul 22
  • Corporate
F. Hoffmann-La Roche Announces 2010 Half Year Results
[PDFPDF 8KB]
Jul 12
  • CSR
Support for Areas Affected by Foot-and-Mouth Disease in Miyazaki Prefecture
[PDFPDF 126KB]

June

Jun 21
  • Product
Anti-Cancer Agent, Herceptin® Designated for Priority Review by Ministry of Health, Labour and Welfare
[PDFPDF 190KB]
Jun 18
  • Product
Recombinant Human Erythropoietin,“EPOGIN® Subcutaneous Injection Syringe 24000,” Approved in Japan
[PDFPDF 183KB]
Jun 18
  • Product
RoACTEMRA: New Hope for Children with Systemic Juvenile Idiopathic Arthritis
[PDFPDF 270KB]
Jun 14
  • CSR
“Transformation in Medical Care & Rheumatoid Arthritis” Chugai Holds an Educational Event at Yurakucho Mullion, Tokyo
[PDFPDF 158KB]
Jun 09
  • Product
New Licence Extension for RoACTEMRA in Europe
[PDFPDF 181KB]

May

May 11
  • Corporate
Determination of Terms and Conditions of Stock Options (Stock Acquisition Rights)
[PDFPDF 80KB]

April

Apr 26
  • Product
RoACTEMRA Recommended for Approval in Europe for the Reduction of Joint Damage and Improvement in Physical Function in Rheumatoid Arthritis
[PDFPDF 195KB]
Apr 23
  • Corporate
Issuance of Stock Options (Stock Acquisition Rights)
[PDFPDF 74KB]
Apr 15
  • Corporate
F. Hoffmann-La Roche Announces First Quarter Sales 2010
[PDFPDF 59KB]

March

Mar 19
  • Product
  • R&D
Anti-Cancer Agents, Herceptin® and Xeloda® Filed for HER2-positive Advanced or Recurrent Gastric Cancer
[PDFPDF 175KB]
Mar 17
  • Product
ACTEMRA(tocilizumab) filed in the US for Prevention of Structural Joint Damage and Improvement of Physical Function in Rheumatoid Arthritis
[PDFPDF 175KB]

February

Feb 19
  • R&D
Chugai to In-license Hedgehog Pathway Inhibitor “RG3616”
[PDFPDF 173KB]
Feb 04
  • Corporate
Personnel Changes
[PDFPDF 172KB]
Feb 03
  • Corporate
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2009
[PDFPDF 67KB]
Feb 03
  • Corporate
Notice Regarding Dividend and the Difference between Dividend Forecast
[PDFPDF 36KB]
Feb 03
  • Corporate
Appointments of Directors
[PDFPDF 12KB]

January

Jan 22
  • CSR
Relief Efforts Support for the Devastating Big Earthquake Disaster Area in Republic of Haiti
[PDFPDF 118KB]
Jan 12
  • Corporate
Chugai Renews its Website for the First Time in Six Years
[PDFPDF 355KB]
Jan 09
  • Product
  • R&D
ACTEMRA®,a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody,Approved in the United States for Rheumatoid Arthritis
[PDFPDF 113KB]
  • Print
  • View in Japanese

Categories

Corporate
Chugai management, including systems, policies and affiliations with other companies as well as financial information
CSR
Environmental measures, social welfare and contributions
Product
Prescription pharmaceuticals which are listed in the official table of drug prices
OTC
Over-the-counter products information up until 2004
R&D
Compounds in development up until the approval stage and technology alliances
Production
Manufacturing facilities, production technologies and product supply plans